Erythromycin Ophthalmic Ointment Shortage Impacts Newborn Infection Prevention Supply
A manufacturer transition has led to a shortage of erythromycin ophthalmic ointment, the sole FDA-approved product for preventing neonatal ophthalmia. Azithromycin is recommended as a temporary clinical alternative.
A change in manufacturing responsibility has caused a significant shortage of erythromycin ophthalmic ointment, the only FDA-approved medication for preventing ophthalmia neonatorum in newborns. This standard post-birth treatment protects infants from serious eye infections.
Health authorities are advising healthcare providers to use azithromycin ophthalmic ointment as a temporary substitute for general ophthalmic uses where erythromycin is typically prescribed. However, azithromycin lacks the same specific FDA approval for newborn prophylaxis.
Professional ophthalmology and surgery organizations have issued joint clinical guidance to help healthcare providers navigate the supply gap. Hospital procurement teams are urged to immediately assess their current inventory and coordinate with health authorities on allocation priorities, especially for maternity and newborn care units.
The shortage is compounded by the continued back order of erythromycin lactobionate injection, a different formulation used for broader infection treatments. This injectable form is not expected to be available until the third quarter of 2026, affecting hospital pharmacies managing treatment protocols for patients with specific bacterial infections or penicillin allergies.
This disruption highlights vulnerabilities in pharmaceutical supply chains, particularly for essential medications with limited alternatives. The transition period for new manufacturers, even when intended to stabilize supply, can create critical gaps, emphasizing the need for careful inventory management and coordination during such changes.